Cheaper cancer care therapy earns big bucks for pharma company
India’s cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country’s emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with…
